🚀 VC round data is live in beta, check it out!
Kamada Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kamada and similar public comparables like Myriad Genetics, Perspective Therapeutics, Benitec Biopharma, Medy-Tox and more.
Kamada Overview
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Founded
1990
HQ
Employees
374
Website
Financials (LTM)
EV
$417M
Kamada Financials
Kamada reported last 12-month revenue of $187M and EBITDA of $45M.
In the same LTM period, Kamada generated $80M in gross profit, $45M in EBITDA, and $23M in net income.
Revenue (LTM)
Kamada P&L
In the most recent fiscal year, Kamada reported revenue of $180M and EBITDA of $42M.
Kamada expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $187M | XXX | $180M | XXX | XXX | XXX |
| Gross Profit | $80M | XXX | $76M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $45M | XXX | $42M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $23M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kamada Stock Performance
Kamada has current market cap of $481M, and enterprise value of $417M.
Market Cap Evolution
Kamada's stock price is $8.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $417M | $481M | 0.7% | XXX | XXX | XXX | $0.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKamada Valuation Multiples
Kamada trades at 2.2x EV/Revenue multiple, and 9.3x EV/EBITDA.
EV / Revenue (LTM)
Kamada Financial Valuation Multiples
As of April 18, 2026, Kamada has market cap of $481M and EV of $417M.
Equity research analysts estimate Kamada's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kamada has a P/E ratio of 21.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $481M | XXX | $481M | XXX | XXX | XXX |
| EV (current) | $417M | XXX | $417M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.3x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBIT | 14.6x | XXX | 15.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | 5.5x | XXX | XXX | XXX |
| P/E | 21.0x | XXX | 23.8x | XXX | XXX | XXX |
| EV/FCF | 15.4x | XXX | 16.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kamada Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kamada Margins & Growth Rates
Kamada's revenue in the last 12 month grew by 11%.
Kamada's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Kamada's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kamada's rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kamada Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kamada Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Imricor Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kamada M&A Activity
Kamada acquired XXX companies to date.
Last acquisition by Kamada was on XXXXXXXX, XXXXX. Kamada acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kamada
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKamada Investment Activity
Kamada invested in XXX companies to date.
Kamada made its latest investment on XXXXXXXX, XXXXX. Kamada invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kamada
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kamada
| When was Kamada founded? | Kamada was founded in 1990. |
| Where is Kamada headquartered? | Kamada is headquartered in Israel. |
| How many employees does Kamada have? | As of today, Kamada has over 374 employees. |
| Who is the CEO of Kamada? | Kamada's CEO is Amir London. |
| Is Kamada publicly listed? | Yes, Kamada is a public company listed on Nasdaq. |
| What is the stock symbol of Kamada? | Kamada trades under KMDA ticker. |
| When did Kamada go public? | Kamada went public in 2013. |
| Who are competitors of Kamada? | Kamada main competitors are Myriad Genetics, Perspective Therapeutics, Benitec Biopharma, Medy-Tox. |
| What is the current market cap of Kamada? | Kamada's current market cap is $481M. |
| What is the current revenue of Kamada? | Kamada's last 12 months revenue is $187M. |
| What is the current revenue growth of Kamada? | Kamada revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Kamada? | Current revenue multiple of Kamada is 2.2x. |
| Is Kamada profitable? | Yes, Kamada is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kamada? | Kamada's last 12 months EBITDA is $45M. |
| What is Kamada's EBITDA margin? | Kamada's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Kamada? | Current EBITDA multiple of Kamada is 9.3x. |
| What is the current FCF of Kamada? | Kamada's last 12 months FCF is $27M. |
| What is Kamada's FCF margin? | Kamada's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Kamada? | Current FCF multiple of Kamada is 15.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.